Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 10 /hr

★★★★★

☆☆☆☆☆

Hire Dr. ASWANI T.

India

USD 10 /hr

PhD Biotechnologist, Microbial Research, Bioactive Compounds & Scientific Consulting.

Profile Summary

I am a Biotechnology PhD with 7+ years of experience in microbiology, microbial biotechnology, and bioactive compound research. My expertise includes microbial isolation, antimicrobial assays, metabolite extraction, and bioprospecting of therapeutically relevant compounds. I also have experience in bioinformatics and genomics data analysis, including molecular docking and biological data interpretation. I have published multiple peer-reviewed articles and hold a patent. In addition, I offer services in scientific writing, literature review, and research consulting. I am committed to delivering accurate, high-quality, and timely results tailored to client needs.

Subject Matter Expertise

• ☆ Drug Discovery
• ☆ High Throughput Screening (HTS)
• ☆ Drug Target Identification
• ☆ Drug Development
• ☆ Drug Substance Characterization
• ☆ Microbiology Testing
• ☆ Drug Stability Testing
• ☆ Preclinical ADME/PK/PD
• ☆ Drug-Drug Interactions
• ☆ Pharmacogenomics
• ☆ In vitro Preclinical Toxciology
• ☆ Drug Efficacy Testing
• ☆ Antibiotic Development
• ☆ Bioavailability
• ☆ Peer Review
• ☆ Research Methodology
• ☆ Literature Search
• ☆ Technical & Scientific Writing
• ☆ Journal Selection
• ☆ Manuscript & Journal Article Writing
• ☆ Experimental Protocols
• ☆ Textbook Content Writing
• ☆ Science Communication

Services

• Writing

Writing Technical Writing

Work Experience

Carbon mannequins

- Present

sustanable product designer

Carbon mannequins

October 2025 - Present

AI Research Scientist

Basesolve

September 2024 - October 2025

Assisitant Professor

REVA University

July 2022 - September 2024

Education

Ph.D-Biotechnology

National Institute of Technology Calicut

January 2016 - November 2021

Certifications

• course completion

  Nitc

  https://drive.google.com/file/d/1rM7sL9w2QpgdzkFT80q2pqGekCDJVZ7r/view?usp=sharing

  September 2021 - Present

Publications

BOOK CHAPTER

ASWANI THEKKANGIL (2023). OCD: Current Diagnostic and Treatment Challenges. Nutrition and Obsessive-Compulsive Disorder.

ASWANI THEKKANGIL (2023). Recent advancement in microbial remediation of heavy metals from industrial effluents . Clean Technologies Toward the Development of a Sustainable Environment and Future.

(2019). Actinomycetes: Its Realm in Nanotechnology . Nanotechnology in the Life Sciences.

JOURNAL ARTICLE

(2020). Antidermatophytic lead compounds from Streptomycetes albidoflavus STV1572a against Tinea infections by Tricophyton mentagrophytes. Microbial Pathogenesis.

(2019). Characterization and antifungal activity of the yellow pigment produced by a Bacillussp. DBS4 isolated from the lichenDirinaria agealita . Saudi Journal of Biological Sciences.

(2019). Water–Chloroform Interface Assisted Microstructure Tuning of Polypyrrole–Silver Sheets . ACS Applied Materials & Interfaces.

(2013). • Comparative analysis of anti-coagulant potential of marine macro algae. International Journal of Pharmacy and Pharmaceutical Sciences.

CONFERENCE PAPER

(2019). Screening of wetland soil actinomycetes for natural pigment:extraction and characterization studies. ICHTR-2019.

(2018). Extraction of antidermatophytic compound from Streptomyces sp.: An antidote for Tinea infection caused by Tricophyton verricosum. Biogenesis -The journal of Biology and Medicine.

(2016). RAPID IDENTIFICATION OF STREPTOMYCES ISOLATES BY MATRIX ASSISTED LASER DESORPTION IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY (MALDI-TOF MS).

Pigment production from endolichenic bacteria.

Target Studies of Potential Antibacterial Compounds from Actinomycetes: A Computer Aided Approach.

“Endolichenic Actinomycetes isolated from Dirinaria aegialita (Afzel. ex Ach.) B.J.Moore and Screening of Antimicrobial Components ”.

“Isolation of endolichenic bioactive Streptomyces spp. From Dirinaria aegialita”.

Endolichenic bacteria from Dirinaria Aegialita: Diversity in Distinct Symbionts.

Actinomycetes derived anti-MRSA drugs targeting to PBP2a.